Sarepta announces plans to price $37.5 million public sale of stock

Bookrunners Credit Suisse and Robert W. Baird to assist with offering

By Devika Patel

Knoxville, Tenn., June 8 – Sarepta Therapeutics, Inc. will raise about $37.5 million in a public offering of common stock, according to a free writing prospectus filed Wednesday with the Securities and Exchange Commission.

Credit Suisse and Robert W. Baird & Co. are the bookrunners.

Proceeds will be used for product and commercial development, manufacturing, business development activities and other general corporate purposes.

Sarepta is a Cambridge, Mass.-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.